Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Rhea-AI Summary

Indaptus Therapeutics (INDP) announces that its Founder and Chief Scientific Officer, Dr. Michael Newman, will take a prominent role at the 6th Annual Cytokine-Based Drug Development Summit in Boston on May 15-16, 2025. Dr. Newman will serve as Chair of Day 2 and deliver a presentation on "Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy" on May 15. He will also lead a panel discussion on pre-clinical models and deliver opening and closing remarks.

The summit, hosted by HansonWade, brings together industry leaders to discuss cytokine drug development challenges and solutions. CEO Jeffrey Meckler highlighted that this invitation demonstrates recognition of the company's novel Decoy platform and Dr. Newman's leadership in cytokine research.

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its Founder and Chief Scientific Officer, Michael Newman, Ph.D., will serve as an Expert Speaker and Chair of Day 2 at the 6^th Annual Cytokine-Based Drug Development Summit taking place May 15-16, 2025 in Boston.

Dr. Newman will deliver a presentation titled “Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy” on Thursday, May 15 at 12:15PM ET. He will also lead a panel discussion on pre-clinical models for cytokine drug development and deliver opening and closing remarks on Day 2 of the conference.

Jeffrey Meckler, Indaptus CEO, commented, “This invitation reflects not only Dr. Newman’s leadership in cytokine research, but also growing recognition of our novel approach at Indaptus. As we to continue to advance our Decoy platform, we are proud to see our science contributing to important industry discussions around improving immunotherapy outcomes.”

The Cytokine-Based Drug Development Summit, hosted by HansonWade, brings together the most influential leaders of the industry to provide practical knowledge, reflective lessons and innovative approaches to overcome challenges with cytokine drug development.

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product candidate, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product candidate. Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

For more information, visit www.indaptusrx.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our expectations and plans regarding our Phase 1 clinical trial of Decoy20 and our anticipated combination study and the anticipated effects of our product candidates, including Decoy20. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2025, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact: investors@indaptusrx.com

Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com

FAQ

What role will Dr. Michael Newman have at the 2025 Cytokine-Based Drug Development Summit?

Dr. Michael Newman will serve as Chair of Day 2 and Expert Speaker, delivering a presentation on pulsed cytokine delivery, leading a panel discussion on pre-clinical models, and giving opening and closing remarks.

When and where is Indaptus Therapeutics (INDP) presenting at the Cytokine Summit?

Dr. Newman will present on Thursday, May 15, 2025, at 12:15 PM ET in Boston during the 6th Annual Cytokine-Based Drug Development Summit.

What is Indaptus Therapeutics' (INDP) main focus as a company?

Indaptus Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for cancer and viral infections through their Decoy platform.

What is the significance of Dr. Newman's participation in the Cytokine Summit for INDP?

According to CEO Jeffrey Meckler, the invitation reflects Dr. Newman's leadership in cytokine research and growing recognition of Indaptus' novel approach in the industry.